Navigation Links
Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
Date:5/5/2008

rts an improvement in skin barrier function. In view of the promising results, the current study has been extended to 48 weeks.

Rosacea is a common chronic facial dermatosis, affecting 14 million Americans, that is characterized by persistent erythema, telangiectasia, papules and pustules. Patients with rosacea are often unable to tolerate extended treatment periods with topical agents as a result of skin sensitivity that accompanies rosacea. Due to the chronic nature of rosacea, there is a continuing need for efficacious treatments that provide sustained relief of its principal signs and symptoms.

Dr. Arisa Ortiz from the University of California Irvine, who is presenting the results of this study at the 2008 International Investigative Dermatology meeting in Kyoto, Japan, stated, "All study subjects reported good tolerability and cosmetic acceptability to Pyratine-6 (TM). The majority of subjects showed reductions in erythema, papules, burning, stinging, and dryness, all of which are signs and symptoms associated with acne rosacea. Transepidermal water loss measurements showed a decrease in water loss which supports an improvement in skin barrier function, attesting to the moisturizing properties of this compound."

Commenting on these findings, Frank Massino, Senetek Chairman and Chief Executive Officer stated, "We are pleased by the positive study findings as this further confirms the excellent safety and effectiveness profile of Pyratine-6(TM). Response to Pyratine-6(TM) in the U.S. physician market has been outstanding and we look forward to expanding our sales and marketing efforts to accommodate increasing demand for this important product."

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products
'/>"/>

SOURCE Senetek, PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... BERWYN, Pa. , July 25, 2014  AMETEK, ... appointment of Kurtis L. Goos as Vice ... Engineered Materials, Interconnects and Packaging (EMIP) Division. ... has extensive general management and business development experience, especially ... to make important contributions to the continued growth and ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... Pediatrics, reacts to a recent study, which shows how grief ... - http://photos.prnewswire.com/prnh/20140723/129709 According to ... stress are more likely than others to grow up overweight ... There were two specific types of stress that ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... XTENT, Inc.,(Nasdaq: XTNT ) today announced a ... Notified Body for CE Mark approval of its ... that recently,presented six-month follow up results from the ... Agency, which reviews the drug formulation,submission of XTENT,s ...
... Make Qnexa the New Clinical Gold, Standard Drug ... Resources, WALTHAM, Mass., June 12 Decision Resources, ... on pharmaceutical and,healthcare issues, finds that a drug that ... would earn a 40 percent patient share in,the obesity ...
Cached Medicine Technology:XTENT Announces European Regulatory Update 2XTENT Announces European Regulatory Update 3A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market 2
(Date:7/25/2014)... July 25, 2014 DON’T PAUSE is a ... uncomfortable bloating, hot flashes, mood swings, burning tongue menopause ... Dr. Shoreh Ershadi. The AntiAging Institute of California is now ... allows women to try this revolutionary product. For a limited ... get a third bottle at no charge. , ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- Dietary changes can dramatically ... a daily basis, according to a new study. ... might help detect and ease flare-ups for people with ... colitis and Crohn,s disease), the researchers said. Trillions ... effect on human health isn,t well understood, the Massachusetts ...
(Date:7/25/2014)... San Francisco, Ca (PRWEB) July 25, 2014 ... in business with their Anniversary Futon Sale. The Futon Shop ... mom and pop shop, which has grown from a few ... States over 33 different kinds of futon mattresses. , ... mouth in the beginning and the desire to sleep on ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 In an election ... it’s no surprise that Americans may not be sleeping well, ... according to a new poll conducted by US-Mattress . ... from across the country, “Which Political Party Do You Side ... that those registered as Independents tout a higher rate of ...
(Date:7/25/2014)... the U.S. are living with a brain tumor, and ... factors, scientists are still searching for answers. , "Right ... and we don,t know why people develop brain tumors," ... Brain Tumor Association. "It,s frustrating for the brain tumor ... funds research to pursue answers to these questions, and ...
Breaking Medicine News(10 mins):Health News:AntiAging Institute of California Now Offers DON'T PAUSE for Menopause with a Special Promotion 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 3Health News:New Study Shows the Growing Number of Independent Voters Have a Greater Propensity for Sleeping Well vs. Democrats or Republicans 2Health News:New Study Shows the Growing Number of Independent Voters Have a Greater Propensity for Sleeping Well vs. Democrats or Republicans 3Health News:Brain tumor causes and risk factors elude scientists 2
... Amilpar,(BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and Reuters: ... today its consolidated,results for the fourth quarter 2007 ... financial information is presented on a consolidated basis,and ... Law and the,Accounts Chart of the Agencia Nacional ...
... 11 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Brothers Global Healthcare Conference on Wednesday, March 19,at ... a live webcast of,the presentation at:, http://cc.talkpoint.com/LEHM002/031808a_jw/default.asp?entity=OnyxPharmaceu ,tic ... on 15 minutes early in order to,register and ...
... new study in the,Journal of the American Medical ... (methicillin-resistant Staphylococus aureus), a simple,skin or nasal swab, ... Screening for Methicillin-Resistant Staphylococcus aureus at,Hospital Admission and ... 10, March 12, 2008)., The findings of ...
... 11 Eli Manning, NFL Most,Valuable Player 2008 ... New,York Giants, will address a National Press Club ... national challenge to encourage Americans to be,more active., ... the President,s Council on,Physical Fitness and Sports, Manning ...
... Inc.,(NYSE: RBN ) announced today that it will ... the period ended February 29, 2008, after,market close on ... conference,call will be held at 2:00 p.m., EDT on ... Chief Executive Officer, and Christopher M. Hix,Vice President and ...
... Center have teased out two distinct sets of risk ... are two completely different kinds of the disease. , ... caused by the human papillomavirus (HPV), a common sexually ... behaviors and marijuana use, rather than tobacco and alcohol. ...
Cached Medicine News:Health News:Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007 2Health News:JAMA Article Provides False Support for CDC's Do-Nothing Position on MRSA 2Health News:Researchers ID behavioral risk factors for head and neck cancers 2Health News:Researchers ID behavioral risk factors for head and neck cancers 3
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... is the newest real-time PCR instrument offered ... offers six detection channels that provide fluorescence ... and 710nm. Perform rapid PCR due to ... with glass capillaries. Virtually any published protocol ...
Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
... standard in QPCR with the Mx4000 multiplex ... superior performance, more flexibility, and reasonable pricing. ... with Windows 98SE and Pentium III (or ... Speakers, Surge Protector (US only), Mx4000 Software ...
Medicine Products: